Maker of devices for surgical treatment of atrial fibrillation and left atrial appendage exclusion, and pain management.
Maker of devices for surgical treatment of atrial fibrillation and left atrial appendage exclusion, and pain management.
Sells disposable devices to hospitals, used once per procedure, so revenue grows with the number of heart surgeries that use them. AtriClip, an implant that closes off a part of the heart where clots form, is the main line. Most sales are in the US.
Moat: narrow (IP / patents, installed base, switching costs). Category-leading AtriClip device with surgeon training and patented technology creates switching costs.
Headquarters: Mason, Ohio · Founded: 2000 · Employees: 1,350
Size AtriCure (ATRC) is a United States Health Care company (Medical Specialties) with a market value of $2.82B, the 1581st largest of 3,085 United States companies the cockpit tracks. Shares closed at $55.45 on 18 Nov 2026.
Performance Over six months the shares gained 91.2%, against -1.3% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 13.8% over the last twelve months (peer median +4.7%); the operating margin is 3.1% (peer median 8.3%).
Valuation It trades at 212.4× forward earnings against a peer median of 24.4× (most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 54% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +33 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.8 points below its cost of capital (11.0% WACC).
Short interest Short interest is 9.6% of the free float (30 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $590M | $535M | $465M | $399M | $330M |
| Revenue growth | — | +15% | +17% | +21% | — |
| Gross profit | $450M | $398M | $345M | $297M | $246M |
| EBITDA | $39.2M | $17.1M | -$9.28M | -$16.3M | -$31.0M |
| Net income | $14.9M | -$11.4M | -$44.7M | -$30.4M | -$46.5M |
| Free cash flow | $52.9M | $48.3M | -$324,000 | -$7.57M | -$39.0M |
| Capital expenditure | $15.6M | $9.05M | $11.5M | $42.0M | $16.9M |
| Total debt | $96.8M | $76.5M | $76.5M | $74.5M | $71.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AtriCure ATRC | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Abbott Laboratories ABT | $181B | +18% | +10% | 14% | 17.9× | 16.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ATRC | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.9% | -2.5% | 11th highest of 21 |
| 6-month return | +91.2% | -1.3% | highest of 21 |
| Distance from 52-week high | -16.0% | -30.5% | 6th highest of 21 |
| Revenue growth (TTM) | +13.8% | +4.7% | 6th highest of 20 |
| Operating margin | 3.1% | 8.3% | 6th lowest of 20 |
| Forward P/E | 212.4× | 24.4× | most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 54.2% | 11.3% | most demanding of 15 |
| Growth delivered (Del g) | +20.9% | +7.6% | 3rd highest of 15 |
| Hurdle (Req g minus delivered) | +33.2 pp | +3.6 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | -7.8 pp | -0.7 pp | 3rd lowest of 19 |
| EV / EBITDA | 69.7× | 20.9× | most expensive of 9 |
| Net debt / EBITDA | -2.3× | 2.4× | least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AtriCure ATRC | United States | $2.82B | +91% | +14% | 3% | 212.4× | 54.2% | +20.9% |
| COMET COTN.SW | Switzerland | $2.78B | -15% | -3% | 6% | 32.8× | n/a | n/a |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |